I am a
Home I AM A Search Login

Papers of the Week

Papers: 26 Mar 2022 - 1 Apr 2022

2022 Mar 08

J Clin Med



Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.


Lo Castro F, Baraldi C, Pellesi L, Guerzoni S
J Clin Med. 2022 Mar 08; 11(6).
PMID: 35329806.


The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of trigeminal excitability. Additionally, clinical data have suggested that an endocannabinoid deficiency is associated with migraine. Given these data, phytocannabinoids, as well as synthetic cannabinoids, have been tried as migraine treatments. In this narrative review, the current clinical evidence of potential ECS involvement in migraine pathogenesis is summarized. Furthermore, studies exploring the clinical effects of phytocannabinoids and synthetic cannabinoids on migraine patients are reviewed.